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Over the last decade, a number of clinical practice 
guidelines that include guidance for the management 
of pediatric asthma have been introduced. (1-3). 
The consistency of pediatric asthma guidelines is 
unknown and the emphasis on establishing asthma 
control may vary. The objective of this paper on 
acute asthma exacerbations in children is to report 
the work of a Task-force constituted of a panel of 
experts, members of the Italian Paediatric Society, 
working in 2007-2008. It was elaborated to provide 
recent information to all caregivers of asthmatic 
children, from the family paediatricians to the nurses 
and physicians working in Emergency Departments 
(ED). This report grades the quality of evidence 
and the strength of recommendations for the 
diagnosis and treatment of acute asthma in children. 
Recommendations may be defective because, in 
children, the use of unlicensed and off-label drugs 
at doses extrapolated from studies performed only 
in adults is frequent.  This aspect may be a potential 
starting point for clinical research in order to 
improve the treatment of children with acute asthma 
exacerbations. 
This update aims to focus on the approach to 
acute asthma exacerbations from the diagnostic and 
therapeutic point of view. 
EDITORIAL
This update on treatment of asthma exacerbations in children is the result of an Italian Pediatric 
Society Task-force, made up of a panel of experts working in 2007-2008. The aim is to give clear indications 
on the use of the drugs most employed in children, grading the quality of evidence and the strength of 
recommendations. Suggestions on their limits due to unlicensed and off-label use are reported. The level 
of evidence and the strength of recommendations for different therapeutic approaches demonstrate 
that frequently the use of drugs in children is extrapolated from the experience in adults and that more 
studies are required to endorse the correct use of different drugs in asthmatic children.
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Partial Arterial CO2 Pressure (Pa CO2) (4-6). 
In children who are not able to perform 
spirometric monitoring, a close clinical monitoring 
should be effectuated to establish the severity of 
asthma. Not all parameters of severity score need to 
be fulfilled to classify asthma severity.
Mild asthma exacerbations, according to the 
suggestions of a recent ATS/ERS task force was 
not taken into consideration in this paper, because 
symptoms or changes in flow rates may reflect 
transient loss of asthma control rather than the early 
stages of severe exacerbation. (7)  
Recommendation
1. In children with acute asthma exacerbation 
SaO2, PEF or FEV1 and, in severe cases, Pa 
CO2 should be evaluated to establish the grade 
of severity. Level of evidence high; benefits 
were substantial; strength of recommendation 
strong (1B).
Great attention must be paid to factors associated 
with severe asthma exacerbations such as previous 
admission to PICU, two or more admissions or 
visits in ED in the last year, usual and/or recurrent 
use of systemic corticosteroids, increased need for 
bronchodilator therapy during the last weeks or 
months, low social economic conditions, etc. 
TREATMENT
Oxygen therapy
The administration of oxygen should be regulated 
by pulse oximetry; children with SaO2 <92% should 
receive humidified oxygen by facemask, or nasal 
cannula with sufficient flow to achieve and maintain 
a normal oxygen saturation (≥ 95%) (4, 8-9). In a 
review (9) of several randomised clinical studies 
(RCS), in which a placebo replaced oxygen therapy, 
it was demonstrated that progressive hypoxemia is 
probably an important cause of death, and oxygen 
should be the first treatment given to any patient 
with acute severe asthma.
Recommendation
2. All children with an acute asthma exacerbation 
should receive humidified oxygen to achieve 
or maintain normal oxygen saturation. Level 
of evidence expert opinion: benefits were 
METHODS
From 2007 until the end of 2008, the Task Force 
was constituted of a panel of experts, members of 
the Italian Paediatric Society, who evaluated articles 
from The Cochrane Register of Controlled Trials 
(CENTRAL), PubMed, EMBASE, the lists of 
references in relevant publications, and the authors’ 
collection of references. Information regarding drugs 
mentioned in the paper are available on the web-
site: http://emc.medicines.org.uk; however, license 
regulations may vary among countries and readers 
are invited to consult their national regulations.
Evidence levels were graded as proposed by the 
BMJ Clinical Evidence Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) 
working group (1). The GRADE score system takes 
into account the type of evidence, the quality, the 
consistency, the directness and the size of the effect; 
evidence was classified as low, fair, moderate, high 
or expert opinion; benefits were described as none, 
conflicting, small/weak, intermediate or substantial; 
strength of recommendation was classified as strong 
or weak (Table I) (1).
Acute asthma is defined as an acute exacerbation 
of wheezing, unresponsive to usually effective 
therapy and necessitating care in an emergency 
room or hospital ward. An acute asthma attack is 
characterized by airway narrowing and inflammation, 
hyperinflation, impairment of pulmonary function, 
alterations in alveolar ventilation and hypoxemia.
Attacks of wheezing induced by upper respiratory 
viral infections are common in pre-school children 
and can be confused with acute asthma exacerbations, 
but they have different treatment strategies.
CLINICAL EVALUATION
Quick and careful clinical evaluation of the 
child, made to assess the severity of acute asthma, is 
essential to develop a therapeutic plan. Anamnestic 
and clinical parameters are fundamental to evaluate 
the patient, even if they have little correlation to the 
severity of each asthma episode (Table II), therefore 
it is necessary to monitor: O2 Saturation (SaO2) (%), 
Peak Expiratory Flow (PEF) or Forced Expiratory 
Volume at 1 second (FEV1) and in severe cases 
L. INDINNIMEO ET AL.
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substantial; strength of recommendation: strong 
(6R).  
Drugs
Drugs normally used in acute asthma and the 
corresponding doses are reported in Table III.
Beta
2
 agonists 
The short-acting beta2 agonists represent the first 
choice treatment in acute asthma exacerbation for 
their bronchodilator effect. 
Continuous inhaled beta-agonist treatment (CBA) 
does not offer advantages compared to intermittent 
treatment. (11-12) As regards the side effects, 
intermittent inhaled beta- agonists, compared to 
CBA, increased the heart rate from baseline (30 
beats/min vs 18 beats/min), but tremor was equally 
common in both treatment groups (RR= 0.56, IC 
95% from 0.21 to 1.40) (11). 
The administration of beta 2 agonist using 
an MDI with spacer is an effective alternative to 
nebulizers for the treatment of children with severe 
or potentially severe acute asthma in the emergency 
department (13). The dose of beta2 agonists 
administered by MDI with spacer must be guided 
by the severity of the acute asthma exacerbation as 
reported in Table III. 
When there is a scarce response to inhaled 
beta2 agonist, salbutamol may be administered 
intravenously, under close clinical monitoring, in 
children admitted to the ED (14).
• Current unlicensed and off-label use 
Salbutamol standard pMDIs and inhalation 
solution are indicated for the relief of bronchospasm 
in children over 2 years of age; although salbutamol 
is widely used in children under 2 years of age. 
Recommendation
3. Nebulised salbutamol should be administered 
every 20-30 minutes and at high cumulative 
doses in severe acute asthma exacerbation. 
Level of evidence: high; benefit: substantial; 
strength of recommendation: strong (1A)
4. Continuous inhaled beta-agonist treatment does 
not offer advantages compared to intermittent 
treatment. Level of evidence: moderate; benefit: 
substantial; strength of recommendation: 
strong.
5. In moderate acute asthma exacerbation the MDI 
with spacer is the optimal device for providing 
beta2 agonists.  Level of  evidence:  high; benefit: 
substantial; strength of recommendation: strong 
(1A).
6. The dose of beta2 agonists administered by 
MDI with spacer must be guided by the severity 
of the acute asthma exacerbation, at least 2-
4 sprays (200-400 mcg), every 20-30’, with 
variable frequency, depending on the clinical 
response. Level of evidence: high; benefit: 
substantial; strength of recommendation: strong 
(1B)
7. Salbutamol (administered intravenously) 
is recommended as an alternative to 
conventional therapy in unresponsive cases 
of life-threatening asthma. Level of evidence: 
moderate-high; benefit: substantial; strength of 
recommendation: strong (2B)
Anticholinergic drugs
Anticholinergic drugs are slower bronchodilatators 
than beta2 agonists; nevertheless, they are synergic. 
Ipratropium bromide is commonly used in children.
Ipratropium bromide  
For children over 2 years of age, and in cases 
of moderate and severe asthma exacerbation, the 
addition of inhaled ipratropium bromide in multiple 
doses to beta2 agonists should be considered  (15). 
A short cut review of 148 papers, carried out to 
establish whether adding inhaled anti-cholinergics 
to beta-agonists improves outcome in the treatment 
of acute childhood asthma, concluded that anti-
cholinergics reduce time to recovery and discharge, 
and may reduce admissions for moderate to severe 
asthmatic children (14). In children under 2 years, 
ipratropium bromide added to beta2 agonists is less 
effective (17). Dosage for children are reported in 
Table III. 
• Current unlicensed and off-label use
Aerocaps of ipratropium bromide are not 
recommended for asthmatic children under 12 years 
of age. A CFC-free inhaler is suggested in asthmatic 
children 6 to 12 years of age or in children under 6 (a 
lower age limit is not specified).
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recommendation: strong (1A). 
10. The use of ICS as an alternative or in addition 
to oral steroids in acute asthma exacerbation. 
ICS is not recommended. Level of evidence: 
moderate; benefit: intermediate; strength of 
recommendation: strong (3C).
Aminophylline
The association of aminophylline IV to beta2 
agonist and of aminophylline IV to beta2 agonist and 
SCS in severe asthma exacerbation does not offer 
significant advantages and it can even cause serious 
side effects; nevertheless some patients benefit from 
this drug. (24) 
• Current unlicensed and off-label use
The use of aminophylline IV in children under 6 
months of age is generally not recommended.
Recommendation
11. Aminophylline therapy is not recommended in 
acute asthma exacerbations in the ED. Level of 
evidence high; benefit intermediate; strength of 
recommendation strong (1A).
12. Aminophylline can be taken into consideration, 
in addition to the usual treatment, in patients 
with respiratory failure and those showing a 
previous satisfactory effect using these drugs. 
Level of evidence: weak; benefit: conflicting; 
strength of recommendation based on expert 
opinion.
Epinephrine
Inhaled epinephrine does not show any 
additional benefit compared with beta-2 agonist in 
the treatment of acute asthma exacerbation and can 
cause side effects, especially in hypoxemic patients 
(25). Dosage for children is reported in Table III. 
• Current unlicensed and off-label use
None when used in asthma
Recommendation
12. Epinephrine (administered subcutaneously or 
intravenously) is not recommended in acute 
asthma exacerbations, it can be used as an 
alternative after I.V. beta-2-agostinst therapy in 
unresponsive cases of life-threatening asthma. 
Level of evidence: weak; benefit: little; strength 
Recommendation
8. For children over 2 years of age, in cases of 
moderate and severe asthma exacerbation 
inhaled ipratropium bromide should be added to 
beta2 agonists. Level of evidence: high; benefit: 
substantial; strength of recommendation: strong 
(1A).
Corticosteroids (CS)
The early use of systemic corticosteroids (SCS) 
in acute asthma exacerbation may reduce the 
frequency of hospitalizations and prevent a relapse 
of symptoms after initial administration.      
SCS must be administered early in the treatment 
of moderate and severe acute asthma exacerbation. 
The SCS need at least 2-4 hours to determine 
a significant clinical improvement. There are 
no significant differences between the methods 
of administration (oral or IV), although oral 
administration is preferred because is less invasive 
and less expensive (18-19). The dosage of oral 
corticosteroids is reported in Table III. Lower doses 
of steroids may be equally effective in children, with 
fewer side effects (20). Experts recommend 3-5 days 
of therapy, excluding the need to taper the SCS at the 
end of the therapy (21).
The scientific evidence is currently insufficient 
to recommend the use of high dose inhaled 
corticosteroids (ICS) as an alternative or in addition 
to oral steroids in acute asthma exacerbation. (22)  
In a recent meta-analysis (23), Rodrigo et al. 
evaluated the effectiveness of ICS in the first 4 
hours from the beginning of treatment in adults and 
children (4 SCR, 285 patients) with acute severe 
asthma. Patients subjected to ICS showed a more 
rapid clinical improvement than those subjected to 
placebo or to SCS, with a 40% reduction of the risk 
of being admitted in the ED in the first 4 hours. 
• Current unlicensed and off-label use
None when used in asthma
Recommendation
9. CSs (oral or IV) should be administered 
early in the treatment of moderate and severe asthma 
exacerbations, with clinical improvement usually 
not before 4 hours after administration. Level of 
evidence: high; benefit: substantial; strength of 
L. INDINNIMEO ET AL.
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of recommendation: strong (4D).
Leukotriene Receptor Antagonists (LRAs)
The effect of LRAs in acute asthma exacerbation 
is, however, not confirmed and leukotriene 
antagonists are not yet established as agents for 
acute management in moderate-severe asthma 
exacerbations in ED. (26)
Recommendation
13. The use of montelukast is not recommended in 
children with acute asthma exacerbation. Level 
of evidence: weak; benefit: little; strength of 
recommendation: strong. 
Magnesium sulfate
Experiences in children are limited and relate to 
a single IV dose, 25-75 mg / kg in 20’ (27); data on 
safety and efficacy of using repeated doses is not 
currently available.
Recent reports indicate the use of isotonic 
solution of MgSO4 with nebulizer in addition to 
bronchodilator in severe asthma; it improves lung 
function, but not the percentage of hospitalizations 
(28). 
• Current unlicensed and off-label use
This drug is not licensed for acute asthma 
exacerbations.
Recommendation   
14. IV Magnesium sulfate (MgSO4) is not 
recommended in children with severe asthma 
exacerbation. It use can be considered in a single 
dose in non-responsive children and/or with 
FEV1 less than 60% after one hour of therapy. 
Level of evidence: high, benefit: little, strength 
of recommendation: strong (1B). 
Heliox 
Helium is a low density gas; therefore the 
inhalation of a mixture containing helium/oxygen 
(Heliox) can reduce respiratory fatigue and improve 
ventilation in patients with obstruction of airways. A 
helium-oxygen mixture (70%/30%) can be used as a 
carrier for administration of inhaled bronchodilators 
in patients with life threatening asthma, after one 
hour of conventional therapy.
This gas can be used, as an alternative to oxygen, 
in severe asthma exacerbation that does not respond 
to initial treatment. (29)  
Recommendation
15. The use of Heliox as an alternative to oxygen 
therapy is not recommended in acute asthma. 
Level of evidence: moderate; benefit: little; 
strength of recommendation: strong (3C).
DEVICES FOR INHALATION IN ACUTE 
ASTHMA EXACERBATION 
Nebulizers, dry powder inhalers (DPI) and MDI 
are the devices used for inhalation in acute asthma 
exacerbations. Use of MDIs with spacers, with/
without facemasks, is recommended for paediatric 
patients. For the effective use of MDIs with spacers, 
it is crucial that the doctor chooses the device that 
is best suited to each patient and that the patient is 
trained on its correct use (30).
Recommendation
16. Use of MDIs with spacers, with/without 
facemasks, is recommended for paediatric 
patients with acute asthma exacerbation. Level 
of evidence: moderate, benefit: substantial, 
strength of recommendation: strong
Hydro-electrolytic balance 
Some children during acute asthma exacerbations 
have variable dehydration and can require adequate 
hydration. Intravenous is preferred if the patient 
vomits, or during severe respiratory distress. An 
excessive intake of fluid must be avoided to prevent 
pulmonary oedema. (31) 
Salbutamol infusions, aminophylline and 
steroids can cause a decrease in blood potassium 
concentrations, with possible side effects on muscle 
contraction and cardiac rhythm; IV potassium 
should be administered, according to the results of 
regular blood controls. (32)
Recommendation
17. In all patients with acute asthma exacerbations 
in the ED dehydration should be prevented, 
especially if IV therapy for severe asthma is 
necessary. Level of evidence expert opinion 
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anaesthesiologist (33).
Recommendation
18. In cases of severe asthma exacerbation 
endotracheal intubation and invasive ventilation 
should be considered. Level of evidence 
expert opinion, benefit: substantial, strength of 
recommendation: strong (6 R). 
OPERATIVE DECISIONS
The level of treatment of an acute asthma 
exacerbation depends on its severity and on the 
response to therapy. The management of acute 
asthma exacerbations starts at home. Most patients 
show a gradual improvement after conventional 
therapy. A minority of them may present a 
progressive clinical deterioration (34) and, if a more 
aggressive treatment is ineffective, they should be 
benefit: substantial; strength of recommendation: 
strong (6 R) 
Endotracheal intubation and invasive ventilation 
Endotracheal intubation should be carried out on 
patients who, despite correct medical therapy and O2 
administration, present:
- a progressive increase of PaCO2
- an exhaustion of respiratory muscle contraction
- persistent hypoxia
- alteration of conscience.
The choice of endotracheal intubation is not 
based on simple evaluation of numerical parameters, 
but on the clinical judgement of an expert team.
Except for respiratory arrest, there are no absolute 
criteria for these procedures. The decision of carrying 
out intubation on a patient cannot be simply based on 
the evaluation of numerical parameters, but on the 
clinical judgement of an expert team, including an 
18
Table I. Key to evidence statements and grades of recommendations.
LEVELS OF  EVIDENCE 
1  Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias  
2 Meta-analyses, systematic reviews, or RCTs with a high risk of bias
3 High quality systematic reviews of case control or cohort or studies 
4 Case control or cohort studies with a high risk of confounding or bias and a significant risk 
that the relationship is not causal
5  Non-analytic studies, e.g. case reports, case series  
6  Expert opinion  
GRADES OF RECOMMENDATIONS 
A At least one meta-analysis, systematic review, or RCT rated as 1, and directly applicable to 
the target population; or a body of evidence consisting principally of studies rated as 1, 
directly applicable to the target population, and demonstrating overall consistency of 
results.
B A body of evidence including studies rated as 2-3, directly applicable to the target 
population, and demonstrating overall consistency of results; or extrapolated evidence from 
studies rated as 1. 
C  A body of evidence including studies rated as 3-4, directly applicable to the target 
population and demonstrating overall consistency of results; or extrapolated evidence from 
studies rated as 3. 
D Evidence level 5 or 6 or extrapolated evidence from studies rated as 3. 
� Good practice points: recommended best practice based on the clinical experience of the 
guideline development group. 
Table I.  Key to evidence statements and grades of recommendations.
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sent to the Emergency Department (ED). 
INDICATIONS FOR HOSPITALIZATION
Panel members do not agree on predictive criteria 
of evolution of an acute asthmatic episode. For 
this reason, it is recommended that the decision of 
hospitalization should be made after the evaluation 
of anamnestic, clinical and functional parameters 
and after a continuous monitoring of the patient. 
Absolute indications for hospitalization are: signs 
and symptoms of acute respiratory failure, worsening 
of clinical parameters after bronchodilator treatment, 
SatO2<92% after bronchodilator treatment, 
concomitant complications (pneumothorax, 
atelectasies, etc.) (Table IV).
19
Table II. Grades of severity of acute asthma exacerbations*.
Grade of severity 
Parameters 
Mild Moderate Severe 
Risk of forthcoming 
respiratory arrest 
Child talks in Sentences Phrases Words - 
Respiratory rate Normal Increased Increased Bradypnea 
Colour Normal Pallor Pallor/Cyanosis Cyanosis 
Alertness Normal Usually agitated Usually agitated Drowsy or confused 
Wheezing End-Expiration Expiration 
Both
Expiration/Inspiration
No audible wheezing 
Use of accessory 
muscles Usually not Moderate Severe Paradoxical breathing
Pulse rate 
(pulse/min) 
Normal Increased Increased Bradycardia 
PEF  FEV1 
% predicted or 
personal best 
> 80% 60-80% 
< 60% 
Not executable 
SaO2% (on air) > 95% 92-95% < 92% <90% 
PaCO2 (mmHg) < 38 38 - 42 >42 >42 
*Note: The presence of several parameters, but not necessarily all of them, indicates the grade of severity of the 
exacerbation. 
Normal breathing rates in conscious children:
< 2 months < 60/min 
2-12 months < 50/min 
1-5 years < 40/min 
6-9 years < 30/min 
10-14 years          <20/min  
Limits of normal pulse rate in children:
0-12 months < 160/min   
>1-2 years < 120/min   
> 2-8 years < 110/min 
Table II. Grades of severity of acute asthma exacerbations*.
*Note: The presence of several parameters, but not necessarily all of them, indicates the grade of severity of the 
exacerbation.
Normal breathing rates in conscious children:
< 2 months < 60/min
2-12 months < 50/min
1-5 years < 40/min
6-9 years < 30/min
10-14 years          <20/min 
Limits of normal pulse rate in children:
0-12 months < 160/min  
1-2 rs < 120/min  
> 2-8 years < 110/min
572 573Int. J. Immunopathol. Pharmacol.
must be minimal, PEF >75%; it is necessary to 
check the child’s ability to correctly operate the 
inhaler, to continue treatment with beta2 agonists 
for at least a week, to consider the use of ICS, to 
deliver written information on the treatment of 
acute exacerbations, and to plan a control visit 
with general practitioner within a week and in a 
RECOMMENDATION
ON DISCHARGE FROM ED
The discharge of a patient should be decided 
after a global evaluation of clinical and functional 
parameters (35-36). 
When the patient leaves hospital, the symptoms 
20
Table III. Drugs and dosages used for treatment of acute asthma exacerbation.
Salbutamol 
� Nebulizer�: 0.15 mg/Kg/dose (1drop = 0.25 mg), to repeat Q 20-30 min, (max 5 mg) 
� MDI (with spacer): 2-4 puffs (200-400 mcg), up to 10 puffs for severe attacks, to repeat, if 
needed, Q 20-30 min during the first hour and then Q 1-4 hours, according to severity  
� Continuous  nebulisation : 0.5-5 mg/Kg/h 
� I. V.: 10 mcg/Kg in 10 min, continue with 0.2/mcg/Kg/min If unsatisfactory response, 
increase the dose by 0.1 mcg/Kg Q 15 min, max 2 mcg/Kg/min 
Ipratropium Bromide 
� Nebulizer�: 125-250 mcg ( < 4 years old ),  250-500 mcg ( > 4 years old ) 
� MDI (with spacer ): 4-8 puffs (80-160 mcg)   
Steroid
� Oral:  prednisone 1-2 mg/Kg/die ( max 40 mg/dose) , in 1-2 administrations; 
              or bethamethasone 0.1 -0.2 mg/Kg/day (max 4 mg/ dose), in 1-2 administrations; 
               or deflazacort 1-2 mg/Kg/day, in 1-2 administrations. 
� IV:  methilprednisolne 1-2 mg/Kg/ 6-8 h (max 40 mg/dose);  
              or idrocortisone 5-10 mg/Kg/6-8 h. 
Aminophylline (Aminophylline = Theophylline / 0.8 ) 
� Start with 6-7 mg/Kg in 50 ml of IV physiologic solution in 20-30 min (2.5 mg/Kg if the 
patient is in therapy with aminophylline)  
� Maintenance: 1 mg/Kg/h IV (<12years); 0.5 mg/Kg/h IV (>12 years); 
Epinephrine  
� Under skin, intramuscular, IV: 0.01 mg/Kg (0.01 ml/Kg of the solution 1:1000) 
Magnesium Sulphate  
� IV: 25  50 mg/Kg in 15-20 min  
�
� Nebulised in 3 ml of saline solution
Table III. Drugs nd dosages use f r tr atment of acute asthma xacerbation.
∗ Nebulised in 3 ml of al e solutio
L. INDINNIMEO ET AL.
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Table IV. Operative decisions. 
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Table IV. Operative decisions.
MODERATE ASTHMA EXACERBATION 
� Salbutamol: inhalation, spray (with spacer) 2-4 puffs (200-400 mcg) max 10 puffs if more severe, or 
nebulizer (0.15 mg/Kg/dose, 1 drop = 0.25 mg), repeat Q 20 min, as needed, up to 3 doses, adding 
Ipratropium bromide spray (with spacer),  4-8 puffs (80-160 mcg) o nebulizer, 125-250 mcg ( < 4 yrs of 
age) and 250-500 mcg (> 4 yrs of age) 
� Steroid: oral prednisone 1-2 mg/Kg/die (max 40 mg/dose) once or twice daily or betametasone 0.1-0.2 
mg/Kg/die (max 4 mg/dose) once or twice daily or deflazacort 1-2 mg/Kg/die, once or twice daily. 
a) Clinical improvement: progressively reduce the frequency of salbutamol and ipratropium bromide, then 
continue only with salbutamol and steroids orally. 
b) Clinical deterioration: Admission to ED.  
Repeat salbutamol with ipratropium bromide, Q 20 min up to 3 doses 
      Continue steroids orally 
O2 therapy 
      b1) if clinical improvement starts, gradually reduce treatment according to clinical response.  
      b2) if clinical conditions deteriorate, treat as a severe asthma exacerbation. 
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SEVERE ASTHMA EXACERBATION 
� Salbutamol: inhalation, spray (with spacer) 2-4 puffs(200-400 mcg) max 10 puffs, or nebulizer (0.15 
mg/Kg/dose), Q 20 min up to 3 doses, together with Ipratropium bromide MDI (with spacer),  4-8 puffs 
(80-160 mcg), or nebulizer, 125-250 mcg  (< 4 yrs of age) and 250-500 mcg (> 4 yrs of age) 
� Steroid: oral prednisone 1-2 mg/Kg/die (max 40 mg/dose) once or twice daily, or betametasone 0.1-0.2 
mg/Kg/die (max 4 mg/dose) once or twice daily, or deflazacort 1-2 mg/Kg/die, once or twice daily;  
systemic metilprednisolone 1-2 mg/Kg/6-8 h (max 40 mg/dose) or idrocortisone 5-10 mg/Kg/6-8 h 
� O2 therapy 
� Admission to ED 
a) Clinical improvement: gradually reduce the frequency of administration of salbutamol and ipratropium 
bromide (initially Q hour for 3 times).  
      Continue steroids and O2, if SaO2 <95% 
b) Clinical deterioration: repeat inhalations Q 20 min up to 3 doses.  
      Continue steroids and O2 
     b1) if clinical improvement starts, gradually reduce treatment according to clinical response 
     b2) if clinical deterioration continues begin more aggressive treatment:  
�   IV Aminophylline: 6-7 mg/Kg in 50 ml of saline solution  in 20-30 min (2.5 mg/Kg, if patient is 
using theophylline); maintenance: 1mg/Kg/h (<12 yrs of age) or  0.5mg/Kg/h (>12 yrs of age) 
�   IV Salbutamol: 10 mcg/Kg (bolus dose) in 10 min, followed by infusion of 0.2 mcg/Kg/min. If no 
response, increase the dose of 0.1 mcg/Kg   Q 15 min, max 2 mcg/Kg/min. 
�    Check blood gases to evaluate  admission to ICU 
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Specialist Asthma Centre within a month. 
CONCLUSIONS
This update on acute asthma exacerbations in 
children is based on evidence statements and grades 
of recommendations.
Although several asthma guidelines providing 
helpful information are available, this paper aims 
to underline some aspects of asthma management in 
children: for example the association of ipratropium 
bromide and beta2 agonists in acute asthma and the 
possible use of magnesium sulphate. Another topic 
is the current use of unlicensed and off-label drugs, 
which is frequent in children and potentially harmful. 
Their use varies from country to country, depending 
on local laws and regulations. This last aspect may 
be a potential starting point for clinical research in 
order to improve the treatment of children with acute 
asthma exacerbations. 
The best strategy, in case of acute asthma 
exacerbation, is to start treatment at home with a 
rapid pharmacologic intervention to prevent the 
worsening of symptoms and to reduce emergency 
visits and hospitalizations. When symptoms 
progressively deteriorate despite pharmacological 
treatment, it is mandatory to send the patient to ED. 
Close cooperation between the paediatrician, general 
practitioner, ED staff, nursing staff and, wherever 
possible, the child and his family is essential for the 
appropriate management of this kind of emergency. 
Diagnostic and therapeutic algorithms simplify the 
clinical management of acute asthma and they are 
a useful educational tool for every professional 
caregiver involved.
ACKNOWLEDGEMENTS
We thank M. Osti, A. Palma, S. Santucci, R. 
Sassi, A. Villani and R. Zanini for their help in 
writing this paper.
REFERENCES
1. British Thoracic Society, Scottish Intercollegiate 
Guidelines Network. British Guideline on the 
Management of Asthma. Available at: http://ww
w.enterpriseportal2.co.uk/filestore/bts/asthma up 
datenov05.pdf. Date last updated: 2005. Date last 
accessed: August 29, 2008.
2. National Health, Lung and Blood Institute. Global 
Initiative for Asthma (GINA). Global Strategy for 
Asthma Management and Prevention. Publication 
n. 95-3659, 1995 Bethesda, Maryland, revised 2006. 
Available at: http://www.ginasthma.org. 
3. National Asthma Education and Prevention Program 
Expert Panel Report 3 (EPR-3): Guidelines for the 
Diagnosis and Management of Asthma-Summary 
Report 2007. J Allergy Clin Immunol 2007; 120(S):
94-138.
4. Carroll CL, Schramm CM, Zucker AR. Severe 
exacerbations in children with mild asthma: 
characterizing a pediatric phenotype. J Asthma 2008; 
45: 513-17.
5. Boychuk RB, Yamamoto LG, DeMesa CJ, Kiyabu 
KM. Correlation of initial emergency department 
pulse oximetry values in asthma severity classes 
(steps) with the risk of hospitalization. Am J Emerg 
Med 2006; 24:48-52.
6. Ducharme FM, Chalut D, Plotnick L, Savdie C, 
Kudirka D, Zhang X, Meng L, McGillivray D. The 
Pediatric Respiratory Assessment Measure: a valid 
clinical score for assessing acute asthma severity from 
toddlers to teenagers. J Pediatr 2008; 152:476-80.
7. Reddel HK, Taylor DR, Bateman ED, et al: American 
Thoracic Society/European Respiratory Society 
Task Force on Asthma Control and Exacerbations. 
An official American Thoracic Society/European 
Respiratory Society statement: asthma control and 
exacerbations: standardizing end points for clinical 
asthma trials and clinical practice. Am J Respir Crit 
Care Med 2009; 180:59-99.
8. Chien JW, Ciufo R, Novak R, Skowronski M, 
Nelson J, Coreno A, McFadden ER Jr. Uncontrolled 
oxygen administration and respiratory failure in 
acute asthma. Chest 2000; 117:728-33.
9. Rodrigo GJ, Rodriquez Verde M, Peregalli V, Rodrigo 
C. Effects of short-term 28% and 100% oxygen on 
PaCO2 and peak expiratory flow rate in acute asthma: 
a randomised trial. Chest 2003; 124:1312-7.
10.  Inwald D, Roland M, Kuitert L, McKenzie SA, 
Petros A. Oxygen treatment for acute severe asthma. 
BMJ 2001; 323:98-100.
11. Camargo CA, Spooner CH, Rowe BH. Continuous 
L. INDINNIMEO ET AL.
574 575Int. J. Immunopathol. Pharmacol.
versus intermittent beta-agonists for acute asthma. 
Cochrane Database Syst Rev 2003; (4):CD001115.
12. Khine H, Fuchs SM, Saville AL. Continuous vs 
intermittent nebulized salbutamol for emergency 
management of asthma. Academ Emerg Med 1996; 
3:1019-24.
13. Sannier N, Timsit S, Cojocaru B, Leis A. Metered-
dose inhaler with spacer vs. nebulisation for severe 
and potentially severe acute asthma treatment in the 
Pediatric Emergency Department. Arch Pediatr 2006; 
13:238-44.
14. Roberts G, Newsom D, Gomez K, et al: North 
West Thames Asthma Study Group. Intravenous 
salbutamol bolus compared with aminophylline 
infusion in children with severe asthma: a randomised 
controlled trial. Thorax 2003; 58:306-10.
15.  Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics 
in the treatment of children and adults with acute 
asthma: a systematic review with meta-analysis. 
Thorax 2005; 60:740-6.
16.  Munro A, Maconochie I. Best evidence topic reports. 
Beta-agonists with or without anti-cholinergics in the 
treatment of acute childhood asthma? Emerg Med J 
2006; 23:470-74.
17.  Everard ML, Bara A, Kurian M, Elliott TM, 
Ducharme F, Mayowe V. Anticholinergic drugs 
for   wheeze in children under the age of two years. 
Cochrane Database Syst Rev 2005; (3):CD001279.
18. Becker JM, Arora A, Scarfone RJ. Oral versus 
intravenous corticosteroids in children hospitalized 
with asthma. J Allergy Clin Immunol 1999; 103:586-
90.
19.  Barnett PL, Caputo GL, Maskin M. Intravenous 
versus oral corticosteroids in the management of 
acute asthma in children. Ann Emerg Med 1997; 29:
212-17.
20. Kayani S, Shannon DC. Adverse behavioral effects 
of treatment for acute exacerbation of asthma in 
children: a comparison of two doses of oral steroids. 
Chest 2002; 122:624-28.
21.  O’Driscoll BR, Kalra S, Wilson M, Pickering CA, 
Carroll KB, Woodcock AA. Double-blind trial of 
steroid tapering in acute asthma. Lancet 1993; 341:
324-27.
22. Edmonds ML, Camargo CA Jr, Brenner BE, Rowe 
BH. Replacement of oral corticosteroids with inhaled 
corticosteroids in the treatment of acute asthma 
following emergency department discharge: a meta-
analysis. Chest 2002; 121:1798-805.
23. Rodrigo GJ. Rapid effects of inhaled corticosteroids 
in acute asthma. An evidence-based evaluation. 
Chest 2006; 130:1301-10. 
24. Mitra A, Bassler D, Goodman K, Lasserson TJ, 
Ducharme FM. Intravenous aminophylline for acute 
severe asthma in children over two years receiving 
inhaled bronchodilators. Cochrane Database Syst 
Rev 2005; (2):CD001276.
25.  Rodrigo GJ, Nannini LJ. Comparison between 
nebulised adrenaline and beta 2 agonists for treatment 
of acute asthma. A meta-analysis of randomised 
trials. Am J Emerg Med 2006; 24:217-22.
26. Mahajan P, Haritos D, Rosenberg N, Thomas R. 
Comparison of nebulised magnesium plus salbutamol 
to nebulised salbutamol plus saline in children with 
mild to moderate asthma. J Emerg Med 2004; 27:21-
5.
27. Kim IK, Phrampus E, Venkataraman S, Pitetti R, 
Saville A, Corcoran T, Gracely E, Funt N, Thompson 
A. Helium/Oxygen-driven salbutamol nebulisation 
in the treatment of children with moderate to severe 
asthma exacerbations: a randomised, controlled trial. 
Pediatrics 2005; 116:1127-33.
28. Dolovich MB, Ahrens RC, Hess DR, Anderson 
P, Dhand R, Rau JL, Smaldone GC, Guyatt G; 
American College of Chest Physicians; American 
College of Asthma, Allergy, and Immunology. 
Device selection and outcomes of aerosol therapy: 
Evidence-based guidelines: American College of 
Chest Physicians/American College of Asthma, 
Allergy, and Immunology. Chest 2005; 127:335-71.
29. Bahna SL, Kaushik SP. Water and electrolyte status 
in children with acute asthma. J Asthma 1984; 21:
73-9.
30. Parr JR, Salama A, Sebire P. A survey of consultant 
practice: intravenous salbutamol or aminophylline 
for acute severe childhood asthma and awareness of 
potential hypokalemia. Eur J Pediatr 2006; 165:323-
25.
31. Soroksky A, Stav D, Shpirer I. A pilot prospective, 
randomised, placebo-controlled trial of bi-level 
positive airway pressure in acute asthmatic attack. 
Chest 2003; 123:1018-25.
576 INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY Vol. 22, no. 4, 0-0 (2009)
0394-6320 (2009)
Copyright © by BIOLIFE, s.a.s.
This publication and/or article is for individual use only and may not be further
reproduced without written permission from the copyright holder.
Unauthorized reproduction may result in financial and other penalties577
32. Stempel DA, McLaughlin TP, Stanford RH. 
Treatment patterns for pediatric asthma prior to 
and after emergency department events. Pediatr 
Pulmonol 2005; 40:310-15.
33. Harvey S, Forbes L, Jarvis D, Price J, Burney P. 
Accident and emergency departments are still failing 
to assess asthma severity. Emerg Med J 2003; 20:
329-31.
34.  Walsh-Kelly CM, Kelly KJ, Drendel AL, 
Grabowaski L, Kuhn EM. Emergency Department 
Revisits for Pediatric Acute Asthma Exacerbations: 
Association of Factors identified in an emergency 
department asthma tracking system. Pediatr Emerg 
Care 2008; 24: 505-10.
 
         
L. INDINNIMEO ET AL.
